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Mitochondrial complex I (CI) deficiency is associ-
ated with multiple neurological and metabolic disor-
ders. However, its effect on innate immunity and
bone remodeling is unclear. Using deletion of the
essential CI subunit Ndufs4 as a model for mito-
chondrial dysfunction, we report that mitochondria
suppress macrophage activation and inflamma-
tion while promoting osteoclast differentiation and
bone resorption via both cell-autonomous and sys-
temic regulation. Global Ndufs4 deletion causes
systemic inflammation and osteopetrosis. Hemato-
poietic Ndufs4 deletion causes an intrinsic lineage
shift from osteoclast to macrophage. Liver Ndufs4
deletion causes a metabolic shift from fatty acid
oxidation to glycolysis, accumulating fatty acids
and lactate (FA/LAC) in the circulation. FA/LAC
further activates Ndufs4/ macrophages via reac-
tive oxygen species induction and diminishes
osteoclast lineage commitment in Ndufs4/ pro-
genitors; both inflammation and osteopetrosis in
Ndufs4/ mice are attenuated by TLR4/2 deletion.
Together, these findings reveal mitochondrial CI as
a critical rheostat of innate immunity and skeletal
homeostasis.
INTRODUCTION
The nuclear-encoded protein NADH: ubiquinone oxidoreduc-
tase iron-sulfur protein 4 (Ndufs4) is critical for mitochondrial
complex I (CI) assembly (Karamanlidis et al., 2013; Kruse et al.,
2008) and identified as a hotspot for mutations (Tucker et al.,
2011). CI is the largest complex in mitochondrial respiratory
chain. Its dysfunction is frequently linked with neurological dis-
eases such as Alzheimer, Parkinson, and Leigh syndrome
(Coskun et al., 2012), as well as metabolic defects such as
impairment of oxidative phosphorylation (OXPHOS; Kirby et al.,
1999). CI is also the site where the respiratory chain generates
reactive oxygen species (ROS; Kushnareva et al., 2002). Physio-
logical changes in ROS production are associated with pro-
cesses such as autophagy, differentiation, metabolic adaption
and immune cell activation (Sena and Chandel, 2012). However,Cell MeROS deregulation is associated with many malfunctions (James
et al., 2012).
Macrophages are essential components of the innate immu-
nity and play a key role in inflammation. Emerging evidence
reveal a tightly controlled crosstalk between metabolism and
inflammation (Tschopp, 2011). Toll-like receptors (TLRs) not
only recognize lipopolysaccharide (LPS) in bacterial cell wall
but also sense nutritional signals such as fatty acids (Baker
et al., 2011; Hotamisligil and Erbay, 2008; Kawai and Akira,
2007). Inflammation is also increasingly recognized as a key fac-
tor in the development of metabolic diseases including obesity,
insulin resistance, type 2 diabetes, and atherosclerosis (Rocha
and Libby, 2009; Schenk et al., 2008). Furthermore, our recent
studies reveal that there is also a delicate balance of metabolism
and inflammation during lactation: maternal genetic defects
such as peroxisome proliferator-activated receptor-g (PPARg)
or very low density lipoprotein receptor deletion, as well as
maternal dietary defects such as high-fat-diet can cause meta-
bolic defects during lactation that lead to the production of ‘‘toxic
milk,’’ which triggers a systemic inflammation in wild-type (WT)
nursing neonates that is manifested as a transient alopecia (Du
et al., 2012a, 2012b; Wan et al., 2007b). We hypothesize that ge-
netic programs also exist in the offspring that allow the suckling
neonates to cope with the lipid- and energy-rich milk produced
by normal lactation and to prevent inflammation. Using alopecia
as readout for neonatal inflammation, here we have identified the
mitochondrial Ndufs4 as part of a critical anti-inflammatory ge-
netic program in the offspring.
Osteoclasts are also derived from the monocyte-macrophage
lineage. Upon binding of RANKL (receptor activator of nuclear
factor kappa-B ligand) to its receptor RANK, macrophage pre-
cursors undergo differentiation into mature osteoclasts that are
multinucleated, specialized, bone-resorbing cells. This process
can be enhanced by other signaling pathways and small mole-
cules such as the nuclear receptor PPARg and its agonist rosigli-
tazone, a widely used diabetes drug (Lazarenko et al., 2007;
Sottile et al., 2004; Wan, 2010; Wan et al., 2007a; Zinman et al.,
2010). Osteoclasts are essential for physiological bone remodel-
ing, deficiency of which can cause osteopetrosis. However,
excessive osteoclasts can cause osteoporosis (Zaidi, 2007). Nu-
clear receptor estrogen-related receptor-a and the transcription
coactivator PGC1bare critical for osteoclast function, implicating
that osteoclastogenesis demands high energy and intact mito-
chondria (Brown and Breton, 1996; Ishii et al., 2009; Wan,
2010; Wei et al., 2010). Here we have identified Ndufs4 as a key
mitochondrial component required for osteoclastogenesis.tabolism 20, 483–498, September 2, 2014 ª2014 Elsevier Inc. 483
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Ndufs4 Regulation of Macrophages and OsteoclastsTo enhance our understanding of the complex disorders asso-
ciated with mitochondrial deficiency, it is pivotal to identify new
mechanisms for how mitochondria modulate cellular and physi-
ological processes. In light of the critical roles of macrophage
and osteoclast in many aspects of physiology and disease, it is
also important to delineate new mechanisms underlying the
control of their lineage specification, differentiation, and func-
tion. Using Ndufs4 deletion as a model for mitochondrial CI
dysfunction, here we show that normal mitochondrial function
suppresses macrophage activation and inflammation while
promoting osteoclast differentiation and bone resorption via
dual mechanisms of both cell-autonomous and systemic
regulation.
RESULTS
Global Ndufs4 Deletion Causes Systemic Inflammation
Manifested as Alopecia
Global Ndufs4 loss in the Ndufs4/ mice results in mitochon-
drial CI deficiency and encephalomyopathy around postnatal
day 30 (P30), leading to lethality at 7 weeks of age (Kruse
et al., 2008). Interestingly, the Ndufs4/ pups also exhibited a
transient alopecia phenotype (Kruse et al., 2008). The first pelage
appeared normal until P16 when precocious hair loss
occurred; the hair loss peaked P20–P24 (Figure 1A), and then
recovered after weaning (P35) when a new coat of hair grew
back. To determine whether the alopecia was dependent on
offspring or maternal genotype, we performed the following ex-
periments. First, when Ndufs4+/ females were bred with
Ndufs4+/ males, 100% of the Ndufs4/ pups and 4% of
Ndufs4+/ pups developed hair loss, whereas all theWT control
pups were normal (Figure 1B). Second, hair loss could not be
rescued when Ndufs4/ pups were fostered by WT lactating
dams (Figure 1B). These results indicate that the alopecia was
caused by the defects in the Ndufs4/ pups rather than in the
Ndufs4+/ dams.
To examine whether the alopecia is associated with excessive
recruitment of myeloid immune cells, we collected skin from
Ndufs4/ and WT littermate controls at P22 and performed
immunofluorescence staining with antibodies for myeloid cell
markers. The skin from Ndufs4/ pups displayed an infiltration
of CD11b+, Gr-1+, and F4/80+ cells, which are largely inflamma-
tory monocytes and macrophages (Figure 1C). In contrast, there
was no overt accumulation of CD11c+ dendritic cells (Figure 1C).
Consistent with these observations, the mRNA levels for a set of
inflammatory markers were elevated in the skin of Ndufs4/
pups (Figure 1D). These results indicate that the alopecia was
likely caused by an inflammatory response during suckling.Figure 1. Global Ndufs4 Deletion Causes Systemic Inflammation Mani
(A and B) Ndufs4/ pups exhibit alopecia. (A) A representative image on postna
(C) Skin of Ndufs4/ pups were infiltrated with leukocytes such as macrophag
(detected by anti-CD11c) on P22. Scale bars represent 25 mm.
(D and E) Expression of inflammatory genes in the skin (D) and liver (E) on P22 (n
(F) Cytokine levels in the serum on P22 (n = 6).
(G and H) Percentage of CD11b+Ly6Chi proinflammatory macrophages in bone m
(I) Expression of inflammatory genes in the primary bone marrow cells or spleno
(J and K) Percentage of CD11b+Ly6Chi proinflammatory macrophages in BM-Mf
(L) Expression of inflammatory genes in BM-Mf cultures on day 6 (n = 5). Error b
Cell MeWe next investigated whether the inflammation was systemic
or skin-specific. First, expression of inflammatory markers was
also elevated in the liver of Ndufs4/ pups (Figure 1E). Second,
serum levels of inflammatory cytokines including interleukin-6,
interferon gamma, and interleukin-12p70 were higher in
Ndufs4/ pups (Figure 1F). Third, the percentage of CD11b+
Ly6Chi proinflammatory monocytes/macrophages was in-
creased in the bone marrow and spleen of Ndufs4/ pups (Fig-
ures 1G and 1H). Fourth, expression of inflammatory markers
was also elevated in primary bone marrow cells and splenocytes
of Ndufs4/ pups (Figure 1I). These results indicate that the
Ndufs4/ pups suffered from systemic inflammation.
To examine if Ndufs4 deletion in the myeloid progenitors con-
fers an intrinsic activation of macrophages, we compared bone
marrow-derived macrophages (BM-Mfs) from Ndufs4/ mice
or WT controls that were differentiated with a defined concentra-
tion of cytokine. Both the percentage of CD11b+Ly6Chi macro-
phages and the expression of inflammatory genes were higher
in the Ndufs4/ cultures (Figures 1J–1L). These results indicate
that the systemic inflammation in Ndufs4/ pups is likely attrib-
uted to, at least in part, cell-intrinsic defects.
Ndufs4/mice exhibited unaltered B cells and T cells, as well
as Th17 and Treg subpopulations (Figures S1A–S1D available
online). In addition to the increased proinflammatory M1markers
in the GMCSF-differentiated Ndufs4/ macrophages and pup
skin (Figures 1D and 1L), there were also decreased anti-inflam-
matory M2 markers in the MCSF-differentiated Ndufs4/ mac-
rophages and pup skin (Figure S1E). Serum corticosterone levels
were normal (Figure S1F). Mitochondrial CI activity was reduced
by >99% in Ndufs4/macrophages (Figure S1G). Furthermore,
treatment with a CI inhibitor rotenone also elevated the expres-
sion of inflammatory genes in WT macrophages (Figure S1J).
These results further indicate that CI deficiency promotes inflam-
matory activation of macrophages.
Global Ndufs4 Deletion Decreases Bone Resorption and
Increases Bone Mass
In light of the potential roles of mitochondria in osteoclast differ-
entiation and bone remodeling, we investigated the skeletal
phenotype in Ndufs4/ mice. Microcomputed tomography
(mCT) analysis of the proximal tibiae from P22 pups revealed
that Ndufs4/ mice exhibited a high-bone-mass phenotype
(Figures 2A–2G). Histomorphometry showed that osteoclast
numbers and surface were decreased, whereas osteoblast
numbers and surfacewere unaltered (Figures 2H and 2I). Consis-
tently, serumbone resorptionmarker CTX-1 (C-terminal telopep-
tides of type I collagen) was 48% lower (Figure 2J), whereas
serum bone formation marker N-terminal propeptide of type Ifested as Alopecia
tal day 22 (P22). (B) Alopecia could not be rescued by WT foster dams.
es (detected by anti-CD11b, anti-F4/80, and anti-Gr-1) but not dendritic cells
= 6).
arrow (BM) and spleen on P22. (G) FACS 2D dot plots. (H) Quantification (n = 5).
cytes on P22 (n = 5).
cultures on day 6. (J) FACS 2D dot plots. (K) Quantification (n = 5).
ars represent SD.
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Ndufs4 Regulation of Macrophages and Osteoclastsprocollagen (P1NP) was normal (Figure 2K). These data indicate
that the high-bone-mass in Ndufs4/ mice was mainly caused
by a compromised osteoclast function.
Ex vivo bone marrow osteoclast differentiation assay using
defined cytokine concentration showed that RANKL-mediated
and rosiglitazone-stimulated osteoclastogenesis was severely
impaired by Ndufs4 deletion. Ndufs4/ cultures exhibited
decreased number and size of multinucleated TRAP+ (tartrate-
resistant acid phosphatase+) mature osteoclasts (Figure 2L),
lower bone resorptive activity (Figure 2M), elevated precursor
proliferation (Figure 2N), and increased apoptosis (Figure 2O).
Moreover, induction of osteoclast differentiation markers, such
as TRAP,CTSK,CALCR, andCAR2,were diminished (Figure 2P);
and induction of osteoclast function genes that promote mito-
chondria biogenesis and oxidative phosphorylation, such as
PGC1b, ATP5b, ATP6V0d2, and ACO2, were severely blunted
(Figure 2Q). CI activity was reduced by >99% in Ndufs4/ oste-
oclasts (Figure S1G). Osteoclast and osteoblast coculture
showed that the osteoclastogenic defects were observed only
when knockout (KO) osteoclast progenitors were cocultured
with WT osteoblasts, but not when WT osteoclast progenitors
were cocultured with KO osteoblasts (Figures S2A and S2B).
Moreover, osteoblast differentiation from Ndufs4/ bone
marrow mesenchymal stem cells was normal (Figure S2C).
These results indicate that CI deficiency causes an intrinsic
defect in osteoclastogenesis, leading to a decreased bone
resorption and an increased bone mass.
Hematopoietic Ndufs4 Deletion Enhances Macrophage
Activation and Inflammation
To further investigate whether CI plays a cell-autonomous role in
macrophage activation and osteoclastogenesis, we generated
hematopoietic Ndufs4 conditional KO mice using Ndufs4flox/flox
mice and Tie2-Cremice. Tie2-Cre deletes flox’d alleles in all he-
matopoietic lineages but not in mesenchymal lineages; thus in
macrophages and osteoclasts but not in osteoblasts (Wan
et al., 2007a, 2007b; Wei et al., 2010). Tie2-Ndufs4 KO mice ap-
peared healthy and survived to adulthood. Interestingly, Tie2-
Ndufs4 KO pups did not exhibit alopecia (Figure 3A). Similar to
Ndufs4/ macrophages, Tie2-Ndufs4 KO macrophages also
showed a >99% reduction in CI activity (Figure S1H), leading
to a higher expression of inflammatory markers (Figure 3B).
These results indicate that CI indeed plays a cell-autonomous
role in macrophages to suppress inflammation.
In contrast to the Ndufs4/ global KO mice, the percentage
of CD11b+Ly6Chi proinflammatory macrophages in the bone
marrow and spleen of Tie2-Ndufs4 KO pups were unaltered (Fig-Figure 2. Global Ndufs4 Deletion Decreases Bone Resorption and Incr
(A–G) Micro-CT analyses of tibiae on P22 (male, n = 8). (A) Representative images
and the entire proximal tibia (bottom; scale bar represents 1mm). (B–F) Quantifica
volume ratio. (C) BS, bone surface. (D) Tb.N, trabecular number. (E) Tb.Sp, trabe
(H and I) Bone histomorphometry (P22, male, n = 8). (H) Osteoclast number (
(Ob.N/B.Ar) and osteoblast surface (Ob.S/B.S; n = 8). B.Ar, bone area.
(J) Serum CTX-1 (P22, male, n = 8).
(K) Serum P1NP (P22, male, n = 8).
(L–Q) Bone marrow osteoclast differentiation assay. (L) Representative images
(>3 nuclei) TRAP+ (purple) cells. Scale bar represents 25 mm. (M) Osteoclast activi
(n = 8). (P and Q) Expression of osteoclast differentiation markers (P) and osteocla
(Veh) control, + compares Ndufs4/ with WT control in the same treatment grou
Cell Meures 3C and 3D). This observation and the absence of the alope-
cia phenotype in Tie2-Ndufs4 KOmice indicate that other tissues
outside of the hematopoietic lineages may also contribute to the
systemic inflammation caused by global CI deficiency.
Ndufs4 Deletion Shifts Metabolism from Fatty Acid
Oxidation to Glycolysis
Mitochondrial CI plays a central role in energy metabolism by
promoting fatty acid b-oxidation and TCA (tricarboxylic acid)
cycle. Because milk provides the suckling neonates rich nutri-
ents such as fat and sugar, we hypothesize that Ndufs4/
pups also exhibit whole body metabolic defects. We found that
serum levels of triglyceride and nonesterified fatty acid (NEFA)
were both 50% higher in Ndufs4/ pups at P22 (Figures 3E
and 3F); at the same time, serum lactate was also 88% higher
(Figure 3G). BM-Mfs from Ndufs4/ mice also produced more
lactate into the culture supernatant, leading to a more acidic
environment (Figure 3H). These results (Figures 3E–3H) indicate
a metabolic shift in Ndufs4/ pups from fatty acid oxidation to
glycolysis, leading to decreased fatty acid catabolism and
increased triglyceride accumulation, and at the same time,
a compensatory elevated glucose catabolism, and lactate
accumulation.
Interestingly, serum levels of triglycerides and lactate were not
significantly altered in Tie2-Ndufs4 KO pups on P22 (Figure 3I),
suggesting that tissues other than the hematopoietic population
were largely responsible for the global metabolic changes. Liver
is a major metabolic tissue in suckling neonates, along with mus-
cle and fat. We found that indeed expression of the proglycolysis
genes Hif1a and Pfkfb2 were upregulated in the liver of
Ndufs4/ pups on P22 (Figure 3J). Thus, we generated liver-
specific Ndufs4 KO using Albumin-Cre mice. CI activity in the
liver was reduced by 84% in Alb-Ndufs4 KO compared to con-
trols (Figure S1I). Serum triglycerides and lactate were 39%
and 30% higher, respectively, in Alb-Ndufs4 KO pups than con-
trols on P22 (Figure 3K). Although the metabolic defects in Alb-
Ndufs4 KO pups were less severe than inNdufs4/ pups, these
results indicate that the liver is the major tissue that mediates CI
regulation of neonatal metabolism; nonetheless, additional tis-
sues such as heart, skeletal muscle, and fat may also contribute
to the global phenotype.
Fatty Acids and Lactate Potentiate the Activation of
Ndufs4–/– Macrophage
We next asked whether the excessive fatty acids as the result of
decreased b-oxidation could potentiate the proinflammatory
phenotype of Ndufs4/macrophages. BM-Mfs from Ndufs4/eases Bone Mass
of the trabecular bone of the tibial metaphysis (top; scale bar represents 10 mm)
tion of trabecular bone volume and architecture. (B) BV/TV, bone volume/tissue
cular separation. (F) Conn.D., connectivity density. (G) Cortical BV/TV.
Oc.N/B.Ar) and osteoclast surface (Oc.S/B.S; n = 8). (I) Osteoblast number
of differentiation cultures on day 12. Mature osteoclasts were multinucleated
ty (n = 8). (N) Osteoclast precursor proliferation (n = 8). (O) Osteoclast apoptosis
st function genes (Q; n = 4). (P and Q) * Compares each treatment with vehicle
p. Error bars represent SD.
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(PA), a representative saturated fatty acid that is abundant in
milk; or linoleic acid (LA), a representative unsaturated fatty
acid. Expression of proinflammatory genes was stimulated by
PA and to a lesser extent by LA in WT macrophages (Figure 3L).
This effect was more pronounced in Ndufs4/ macrophages,
which already exhibited higher basal expression thanWTmacro-
phages (Figure 3L). Similarly, lactate also increased the expres-
sion of proinflammatory genes in WT macrophages, and more
dramatically in Ndufs4/ macrophages (Figure 3M).
The percentage of CD11b+Ly6Chi proinflammatory macro-
phages in the bone marrow of Alb-Ndufs4 KO pups was higher
than controls (Figure 3N). Moreover, the expression of inflamma-
tory genes in the spleen was increased in Alb-Ndufs4 KO pups
and Tie2-Ndufs4 KO pups, and further potentiated in Alb+Tie2-
Ndufs4 double KO (DKO) pups (Figure 3O). These results indi-
cate that the combination of the intrinsic defects in Ndufs4/
macrophages and the systemic metabolic defects of FA/LAC
accumulation in the circulation of the Ndufs4/ pups lead to
an exacerbated macrophage activation and systemic inflamma-
tion comparedwithWTmacrophages in the normal environment.
Alb-Ndufs4 KO pups or Alb+Tie2-Ndufs4 DKO pups also did not
exhibit alopecia (Figure 3P), suggesting that Ndufs4 deletion in
other metabolically active tissues, such as heart, skeletal mus-
cle, and fat, may be also required to replicate metabolic and in-
flammatory defects as severe as in the global Ndufs4/ pups.
ROS Production Is Elevated in Ndufs4–/– Macrophages
and Exacerbated by Fatty Acids
Mitochondria-derived ROS is critical for macrophage activation
(West et al., 2011). Thus, we next investigated if the exacerbated
inflammation by Ndufs4 deletion is contributed by excessive
ROSproduction in vivo and in vitro. Quantified byMitoSOX stain-
ing (Misawa et al., 2013; Zhou et al., 2011), ROS was found to be
more abundant in the skin, bone marrow, and spleen of
Ndufs4/ pups compared with WT controls (Figures 4A and
4B). The ROS level was much higher in Ndufs4/ BM-Mfs and
was further increased by PA treatment (Figure 4C). Mitochondrial
membrane potential was lower inNdufs4/ BM-Mfs and further
decreased by PA (Figure 4D). In line with the increased ROS pro-
duction and oxidative stress, the expression of the stress sensor
genes Gadd45a/b, as well as apoptosis, was also higher inFigure 3. Ndufs4 Deletion Shifts Metabolism to Potentiate Macrophag
(A) Representative image showing that Tie2-Ndufs4 KO mice had no alopecia.
(B) Expression of inflammatory genes in Tie2-Ndufs4 KO BM-Mfs was increased
(C and D) Percentage of CD11b+Ly6Chi proinflammatory macrophages in the b
(C) FACS 2D dot plots. (D) Quantification (n = 5).
(E–G) Serum triglycerides (E), nonesterified fatty acid (NEFA) (F), and lactate (G)
(H) Ndufs4/ macrophages secrets more lactic acid. Left, images showing the
tification of lactate in culture medium (n = 6).
(I) Serum triglycerides (left) and lactate (right; n = 8).
(J) Expression of Hif1a and Pfkfb was higher in the liver of Ndufs4/ mice (n = 5
(K) Serum triglycerides (left) and lactate (right) in Alb-Ndufs4 KO mice and contro
(L andM) Fatty acids (L) and lactate (M) potentiate the activation of inflammatory g
(PA) or linoleic acid (LA; 400 mM) or lactate (15 mM) for 15 hr.
(N) Percentage of CD11b+Ly6Chi proinflammatory macrophages in the bone ma
(O) Expression of inflammatory genes in the spleen was increased in Tie2-Ndufs4
on P22 (n = 5).
(P) Alb-Ndufs4 and Alb+Tie2-Ndufs4 DKO mice had no alopecia.
Error bars represent SD.
Cell MeNdufs4/ macrophages and further potentiated by PA (Figures
4E and 4F). Importantly, PA induction of ROS (Figure 4G) and
proinflammatory genes (Figure 4H) was attenuated by the mito-
chondrial ROS inhibitor 2R,4R-APDC (2R,4R-aminopyrrolidine
dicarboxylate). Mito-TEMPO, another mitochondria-targeted
antioxidant and a specific scavenger of mitochondrial ROS,
also attenuated PA induction of ROS (Figure 4G), inflammatory
genes (Figure 4I), and stress sensor genes (Figure 4J). These
findings indicate that increased mitochondrial ROS production
represents an important mechanism underlying the systemic
inflammation in Ndufs4/ suckling neonates.
Inflammation and Alopecia in Ndufs4–/– Pups Can Be
Rescued by TLR4/2 Deletion
Fatty acids and lactate induce inflammation and insulin resis-
tance via TLR4/2 (Samuvel et al., 2009; Senn, 2006; Shi et al.,
2006). To further investigate the significance of the excessive
FA/LAC in the systemic inflammation in Ndufs4/ pups in vivo,
we examined whether the alopecia could be rescued by TLR4/2
deletion. Ndufs4/TLR2/TLR4 triple KO (TKO) mice were com-
pletely resistant to hair loss (Figure 5A). Consistent with this
observation, the excessive macrophage infiltration (Figure 5B)
and proinflammatory gene expression (Figure 5C) in the skin of
Ndufs4/ pups were ameliorated in Ndufs4/TLR2/TLR4 TKO
pups. Moreover, PA-stimulated inflammatory gene expression
(Figure 5D) and ROS production (Figures 5E and 5F) inNdufs4/
macrophages was also dampened by TLR2/4 deletion. Serum
NEFA, triglyceride, and lactate were unaffected by TLR2/4 dele-
tion because they were elevated to a similar extent in both
Ndufs4-KO and Ndufs4/TLR2/4 TKO (Figure 5G), indicating
that the metabolic defects remained, but the response to this
metabolic shift was abolished by TLR2/4 deletion.
Further genetic dissection revealed that although TLR2/4
double deletion has the strongest rescue effects, TLR4 dele-
tion alone, but not TLR2 deletion alone, also conferred signifi-
cant attenuation of the alopecia, indicating that TLR4 is the
major mediator of the inflammation in the Ndufs4/ neonates
(Figure 5H).
This genetic evidence promoted us to investigate whether
pharmacological inhibition of TLR4 can ameliorate the inflamma-
tion in Ndufs4/ neonates, using alopecia as a convenient
readout. The results showed that Ndufs4/ pups treated withe Activation
on day 6 (n = 3).
one marrow (BM) and spleen was normal in Tie2-Ndufs4 KO pups on P22.
were increased in Ndufs4/ pups (n = 8).
medium of Ndufs4/ BM-Mf cultures was more acidic (yellow). Right, quan-
).
ls (n = 8).
enes inNdufs4/macrophages (n = 5). BM-Mfs were treatedwith palmitic acid
rrow (BM) was increased in Alb-Ndufs4 KO pups on P22 (n = 5).
KO and Alb-Ndufs4 KO, and further potentiated in Alb+Tie2-Ndufs4 DKOmice
tabolism 20, 483–498, September 2, 2014 ª2014 Elsevier Inc. 489
WT Ndufs4-/-
0.00
0.05
0.10
0.15
COX-2
****
****
WT Ndufs4-/-
0.00
0.02
0.04
0.06
0.08
IL-1b
R
el
at
iv
e 
m
RN
A 
in
 M
f
Veh
PA
PA+APDC
*
****
WT Ndufs4-/-
0.000
0.001
0.002
IL-12p35
*
**
WT Ndufs4-/-
0.000
0.001
0.002
IL-12p40
*
**
H
Mito-SOX
W
T
N
du
fs
4-
/-
DAPI Merge
Re
la
tiv
e 
M
ito
-S
O
X
Bone Marrow Spleen
0
1
2
3
****
***
Ndufs4-/-
WT
BA
W
T
N
du
fs
4-
/-
M
ito
-S
O
X
20.5 44.3 24.2
FL1
13.1 23.7 13.3
Veh PA LA DC
R
el
at
iv
e 
m
RN
A
Veh PA
0.000
0.001
0.002
0.003
0.004
0.005
*
Ndufs4-/-
WT
****
Gadd45a
++
++++
Veh PA
0.00
0.05
0.10
0.15
*
**
Gadd45b
++
++
An
ne
xi
nV
+ 
7A
AD
- (
%
)
Veh PA
0
20
40
60
80
****
***
+
+++
WT
Ndufs4-/-
GE
JI
WT Ndufs4-/-
0
1
2
3
4
5
M
ac
ro
ph
ag
e 
M
ito
-S
O
X
Veh
PA
PA+APDC
****
PA+Mito-TEMPO
***
***
**** ****
****
WT Ndufs4-/-
0.00
0.02
0.04
0.06
0.08
0.10
COX-2
***
***
WT Ndufs4-/-
0.00
0.02
0.04
0.06
IL-1b
R
el
at
iv
e 
m
RN
A 
in
 M
f
Veh
PA
**
**PA+Mito
-TEMPO
WT Ndufs4-/-
0.000
0.001
0.002
0.003
IL-12p35
*
***
WT Ndufs4-/-
0.000
0.001
0.002
IL-12p40
*
*
WT Ndufs4-/-
0.000
0.001
0.002
Gadd45a
**
**
WT Ndufs4-/-
0.00
0.05
0.10
0.15
0.20
0.25
Gadd45b
*
**
WT Ndufs4-/-
0
20
40
60
80
100
M
em
br
an
e 
Po
te
nt
ia
l: 
De
ep
 R
ed
 (%
)
Veh
PA
LA
****
****
+++
+++
+++
n.s.
n.s.
WT Ndufs4-/-
0
1
2
3
4
M
ac
ro
ph
ag
e 
M
ito
-S
O
X
Veh
PA
LA
*
**
++
++
++
n.s.
n.s.
F
(legend on next page)
Cell Metabolism
Ndufs4 Regulation of Macrophages and Osteoclasts
490 Cell Metabolism 20, 483–498, September 2, 2014 ª2014 Elsevier Inc.
Cell Metabolism
Ndufs4 Regulation of Macrophages and Osteoclaststhe TLR4 inhibitor TAK-242were spared from hair loss (Figure 5I).
These findings uncover TLR4 as an essential mediator of the sys-
temic inflammation in theNdufs4/ pups, and highlight TLR4 in-
hibitors as an effective treatment of this mitochondrial disorder.
Hematopoietic Ndufs4 Deletion Impairs
Osteoclastogenesis and Bone Resorption
We next examined the hematopoietic-intrinsic regulation of
osteoclastogenesis by CI using the Tie2-Ndufs4 KO mice. Oste-
oclast differentiation and function from Tie2-Ndufs4 KO bone
marrow were severely impaired (Figures 6A–6D), causing a
41% lower serum CTX-1 (Figure 6E) and a higher bone mass
(Figures 6F and 6G). We have also generated myeloid-specific
Ndufs4 KO mice using the Lysozyme-Cre mice (Lyz-Ndufs4). A
time course analysis of osteoclast differentiation revealed that
Ndufs4 deletion was later and less complete in Lyz-Ndufs4
cultures than Tie2-Ndufs4 cultures, leading to a less severe oste-
oclast differentiation defect (Figures S5A–S5E). Nonetheless,
Lyz-Ndufs4 KO mice also showed a similar phenotype as Tie2-
Ndufs4 KO mice with lower bone resorption, higher bone
mass, and elevated inflammatory gene expression in the spleen
(Figures S5F–S5M). These results indicate that CI plays a cell-
intrinsic role in the osteoclast lineage to promote osteoclasto-
genesis and decrease bone mass.
Interestingly, Ndufs4 deletion in the liver also significantly
elevated the bone mass in the Alb-Ndufs4 KO mice (Figures 6F
and 6G). Moreover, Ndufs4 deletion in both osteoclast and liver
as in the Alb+Tie2-Ndufs4 DKO mice further increased bone
mass compare to individual single KO (Figures 6F and 6G).
Osteoclast surface (Figure 6H) and serum CTX-1 (Figure 6I)
were also lower in Alb-Ndufs4 KO mice and further decreased
in Alb+Tie2-Ndufs4 DKO mice; whereas serum P1NP was unal-
tered (Figure 6J). These results indicate that CI promotes osteo-
clastogenesis and bone resorption through both cell-intrinsic
and systemic metabolic mechanisms.
In light of the dual regulation of bone resorption and inflamma-
tion by CI, we next examined an LPS-induced inflammatory
arthritis model (Chang et al., 2008; Jimi et al., 2004; Takayanagi
et al., 2000; Zhao et al., 2009). LPS induction of bone resorption
and bone losswas abolished in Alb-Ndufs4 KO, Tie2-Ndufs4 KO,
and Alb+Tie2-Ndufs4 DKO mice (Figures S3A–S3C), despite the
exacerbated inflammation (Figure S3D). This indicates that
osteoclastogenic defects are dominant over inflammatory de-
fects in the context of inflammatory arthritis, and mitochondrial
CI inhibition may confer resistance to inflammation-induced
bone loss.Figure 4. ROS Level Is Elevated in Ndufs4–/– Macrophages and Exacer
(A) Representative images of Mito-SOX staining of skin on P22. Scale bars repre
(B) FACS quantification of Mito-SOX levels in bone marrow and spleen on P22 (n
(C) Mito-SOX levels in BM-Mfs treated with PA or LA (400 mM). Left: FACS 2D do
(D) Mitochondrial membrane potential was decreased in Ndufs4/ macrophage
MitoTracker deep red via FACS.
(C and D) * and n.s. compare treatment with vehicle control in the same genotyp
(E and F) Expression of the stress sensor genes Gadd45a/b (E) and apoptosi
(n = 3). * compares Ndufs4/ with WT under the same treatment; + compares P
(G) PA induction of mitochondrial ROS in macrophages, measured byMito-SOX, w
(H and I) ROS inhibitors 2R,4R-APDC (H) or Mito-TEMPO (I) partially rescued the P
(J) Mito-TEMPO partially rescued the PA-activated stress sensor gene expressio
with or without APDC or Mito-TEMPO (50 mM). Error bars represent SD.
Cell MeFatty Acids and Lactate Exacerbate the
Osteoclastogenic Defects in Ndufs4–/– Cells
Macrophage activation and osteoclast maturation represent two
divergent and competing differentiation outcomes for monocyte
precursors. The findings that the excessive FA/LAC inNdufs4/
mice potentiate macrophage activation, and liver Ndufs4 dele-
tion also decrease bone resorption, prompted us to investigate
whether FA/LAC also suppress osteoclast differentiation and
lineage allocation. Osteoclast differentiation from WT bone
marrow was suppressed by fatty acids such as PA and LA (Fig-
ures 7A–7C); in contrast, osteoblast differentiation was unaf-
fected (Figure S2D). Moreover, fatty acids exacerbated the
osteoclastogenic defects in Ndufs4/ cells, leading to a further
reduction in osteoclast differentiation (Figures 7A–7C). Lactate
had similar effects (not shown). RANK and FMS are two recep-
tors that define osteoclast precursors and are functionally
required for osteoclastogenesis in response to RANKL and
MCSF. The percentage of FMS+RANK+ osteoclast precursors
was lower in the bonemarrow ofNdufs4/mice andAlb-Ndufs4
KO mice (Figures 7D and S6A). Similarly, the percentage of
FMS+RANK+ osteoclast precursors was also reduced in
Ndufs4/ osteoclast differentiation cultures (Figure 7E). The
osteoclastogenic defects in Ndufs4/ cultures could not be
rescued by higher RANKL concentrations (Figure S4A), further
supporting the severely compromised RANK level. Decreased
FMS level in Ndufs4/ cultures was only observed during oste-
oclast differentiation after RANKL treatment but not during pro-
liferation (Figure S4B), in agreement of the specific impairment
of osteoclast differentiation but not precursor proliferation (Fig-
ures 2L–2N). Because the osteoclastogenic defects inNdufs4/
cultures were associated with reduced expression of not only
FMS and RANK, but also NFATc1 and c-fos, two key transcrip-
tion factors for osteoclast differentiation, we examined the
importance of each factor in this regulation. The results show
that overexpression of FMS, RANK and NFATc1, but not c-fos,
was able to partially rescue the osteoclastogenic defects (Fig-
ures S4E–S4L).
Interestingly, the percentage of FMS+RANK+ osteoclast pre-
cursors in WT and Ndufs4/ cultures was further diminished
by PA, LA, or lactate (Figure 7E). The antiosteoclastogenic
effects of PA, LA, or lactate remained when the treatment was
restricted to only the first 3 days after RANKL treatment and
then removed (Figure S4C), further supporting that the regulation
resides mainly in the precursor stage. In line with this in vitro
finding, WT mice treated with PA and LA for 2 weeks displayed
a decreased bone resorption and an increased bone massbated by Fatty Acids
sent 25 mm.
= 5).
t plots. Right: quantification (n = 5).
s and further reduced by PA, but not LA (n = 5), quantified by percentage of
e; + compares Ndufs4/ with WT in the same treatment group.
s (F) were higher in Ndufs4/ macrophages and further potentiated by PA
A with vehicle in the same genotype.
as abolished by ROS inhibitors 2R,4R-APDC (50 mM) or Mito-TEMPO (50 mM).
A-activated inflammatory gene expression inWT andNdufs4/macrophages.
n in WT and Ndufs4/macrophages. BM-Mfs were treated with PA (400 mM),
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Figure 5. Inflammation and Alopecia in Ndufs4–/– Pups Can Be Rescued by TLR2/4 Deletion
(A–F) Comparison of Ndufs4/TLR4/TLR2 triple KO, Ndufs4/, and WT controls on P22 (n = 4).
(A) Representative images showing alopecia phenotype.
(B) CD11b immunostaining of skin. Scale bars represent 25 mm.
(C) Expression of inflammatory genes in the skin.
(D) Expression of inflammatory genes in BM-Mfs treated with PA or vehicle (Veh).
(legend continued on next page)
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phage precursors was normal (Figure S6B). TLR2/4 deletion
partially rescued the bone resorption defects in Ndufs4/
mice both in vivo (Figure 7F) and in vitro (Figure 7H), whereas
bone formation was unaffected (Figure 7G). Consequently, the
high bone mass in Ndufs4/ mice was attenuated in Ndufs4/
TLR2/4-TKO mice (Figure S6C). These results provide critical
mechanisms for the low bone resorption and high bone mass
in mitochondrial dysfunction: CI deficiency reduces bone
resorption by inhibiting both osteoclast differentiation and oste-
oclast lineage allocation via both cell-intrinsic defects and sys-
tematic metabolic defects.
DISCUSSION
Our study uncovers a critical yet previously unrecognized role of
mitochondrial CI in macrophage-osteoclast polarization to sup-
press systemic inflammation but enhance bone resorption. This
regulation involves mechanisms at both cell-intrinsic and sys-
temic levels (Figure 7I). First, CI in the myeloid precursors
impedes inflammatory responses in macrophages but activates
osteoclast differentiation by functioning in a cell-autonomous
manner. Second, CI in metabolically active tissues such as liver
shifts metabolism from glycolysis to fatty acid oxidation, leading
to less accumulation of fatty acids and lactate in circulation,
which in turn further dampen macrophage activation and
enhance osteoclast differentiation via TLR4/2 signaling. Further-
more, CI favors osteoclastogenesis over macrophage activation
at several stages by modulating lineage allocation, differentia-
tion, and activity. Therefore, mitochondrial CI orchestrates an
intricate regulatory program to synergistically control physiology
and disease.
Using primary bone marrow osteoclast differentiation assays,
we found that fatty acids, such as PA and LA, suppress osteo-
clastogenesis by inhibiting osteoclast differentiation and dimin-
ishing FMS and RANK expression in osteoclast precursors.
The antiosteoclastogenic effects of fatty acids have also been re-
ported in other studies (Cornish et al., 2008). Importantly, our
ex vivo observations were also supported by in vivo findings
that the increased serum levels of fatty acids in the Ndufs4/
and Alb-Ndufs4-KO mice, as well as PA+LA treated mice, led
to lower bone resorption and higher bone mass. Using
RAW264.7 macrophage cell line, a recent report shows that PA
may enhance osteoclast differentiation by increasing tumor
necrosis factor alpha (Drosatos-Tampakaki et al., 2014). This
discrepancy may be explained by the differences in the culture
systems, for example, PA treatment of an immortalized cell line
may not reflect the full effects of PA on the entire osteoclast dif-
ferentiation process.
Inflammation-induced bone erosion such as in arthritis is a
highly prevalent disorder. In line with the report that rotenone
treatment attenuates LPS-induced bone loss (Kwak et al.,
2010), our genetic dissection reveals that Ndufs4 deletion con-(E and F) Mito-SOX levels in BM-Mfs treated with PA (400 mM). (E) FACS 2D dot
(G) TLR2/4 deletion did not alter the metabolic defects in Ndufs4/ mice (n = 5)
(H) Alopecia in Ndufs4/ pups was rescued by TLR4 deletion but not TLR2 dele
(I) Alopecia in Ndufs4/ pups was rescued by TLR4 inhibitor TAK-242 (P22). N
starting P1. Error bars represent SD.
Cell Mefers resistance to inflammation-induced bone erosion via both
osteoclast-intrinsic and metabolic/systemic regulation. These
findings highlight the exciting therapeutic potential of mitochon-
drial CI inhibition in treating bone degenerative diseases.
In our previous studies, we identified maternal genetic and di-
etary factors as key regulators of lactation, milk quality, and
neonatal inflammation (Du et al., 2012a, 2012b; Wan et al.,
2007b). In this study, we identified mitochondrial CI as a critical
neonatal genetic program that is essential for the postnatal
metabolic adaptation to prevent inflammation and ensure normal
bone remodeling. Ndufs4 deletion inmice causes early postnatal
lethality with metabolic defects including increased serum tri-
glycerides and lactic acid; similarly, human mitochondrial CI
deficiency also leads to disorders with early childhood onset
(Distelmaier et al., 2009) that are manifested asmetabolic abnor-
malities including fatal infantile lactic acidosis (FILA; Loeffen
et al., 2000; Smeitink et al., 2004). Similar to the alopecia in
Ndufs4/ mice, human patients with mitochondrial mutation
also often have skin or hair problems, which are already
accepted as an indicator of mitochondrial defects in clinic (Bod-
emer et al., 1999; Kubota et al., 1999; Silengo et al., 2003). This
in vivo study reveals systemic inflammation as a key etiology for
mitochondrial diseases in a unique natural metabolic context of
lactation and suckling neonates. Several prevalent and devas-
tating infantile disorders, such as necrotizing enterocolitis, still
have no known causes or effective treatments. Future clinical in-
vestigations will further examine whether inflammation andmito-
chondrial dysfunction contribute to these newborn diseases.
Importantly, our findings not only elucidate the mechanisms
underlying the neonatal defects in systemic inflammation and
low bone resorption caused by mitochondrial CI deficiency,
but also uncover TLR4 inhibition as a potential treatment of infan-
tile disorders and mitochondrial diseases.
EXPERIMENTAL PROCEDURES
Mice
Ndufs4/ andNdufs4flox/floxmice (Kruse et al., 2008; backcrossed to C57BL/6
mice for >15 and 7 generations, respectively) were provided by Dr. Richard
Palmiter (University of Washington). Tie2-Cre (Kisanuki et al., 2001), Lyso-
zyme-Cre, and Albumin-Cre (Jackson Laboratory) transgenic mice were main-
tained on a pure C57BL/6 background. To generate hematopoietic-, myeloid-,
and liver-specific Ndufs4 KO mice, Ndufs4flox/flox mice were bred with Tie2-
Cre+/, Lyz-Cre+/ or Alb-Cre+/ mice, respectively; the Ndufs4flox/+Cre+/
F1 mice were bred with Ndufs4flox/flox mice to obtain Ndufs4flox/floxCre+/ F2
mice, which were bred with Ndufs4flox/flox mice to generate Ndufs4flox/flox
Cre+/ mice and littermate Ndufs4flox/floxCre/ controls. TLR2/4 DKO mice
on a pure C57BL/6 background (Hoshino et al., 1999; Takeuchi et al., 1999)
were bred with Ndufs4+/ mice to generate Ndufs4/TLR4/TLR2 triple KO
mice, Ndufs4/TLR4 or Ndufs4/TLR2 double KOmice, and Ndufs4 KO controls.
All experiments were conducted using littermates. Mice were fed ad libitum
with standard chow (Harlan Laboratories). Serum triglyceride and lactate
levels were measured using a Vitros-250 chemistry analyzer at UTSW Meta-
bolic Phenotyping Core. Serum nonesterified fatty acids were measured using
the NEFA-HR assay (Wako). The same panels of cytokines were analyzed for
expression, and only the ones with significant changes are shown to beplots. (F) Quantification (n = 5).
.
tion (P22).
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tee of UTSW.
Immunofluorescence Staining and Fluorescence-Activated Cell
Sorting
Frozen sections were stained with FITC-CD11b, FITC-Gr-1, FITC-CD11c (BD
Biosciences), or FITC-F4/80 (Serotec), washed twice, and mounted with
medium containing DAPI (Vector Laboratories). Fluorescence-activated cell
sorting (FACS) was conducted with FACSCalibur using FITC-Ly6C, PE-
CD11b (BD Biosciences), PE-RANK, and APC-FMS (eBioscience).
Mitochondrial ROS, Membrane Potential, and CI Activity
To detect mitochondrial-generated ROS by FACS, cells were detached from
culture plates with Cell Dissociation Buffer (Life Technologies) and washed
in cold PBS. Detached cells or primary bone marrow and spleen cells were
incubated with Mito-SOX red mitochondrial superoxide indicator (Life Tech-
nologies) at 37C for 20 min, washed twice with PBS, and then analyzed
with flow cytometry. To detect mitochondrial ROS in skin, frozen skin sections
were incubated with Mito-SOX at 37C for 20 min, washed, and counter-
stained with DAPI before image acquisition. To quantify mitochondrial mem-
brane potential, cells were stained with MitoTracker deep red (a fluorescent
probe sensitive to the membrane potential) and MitoTracker green (a probe
that stains mitochondrial membrane lipids independently of membrane poten-
tial), and the percentage of deep red-positive cells was quantified (Nakahira
et al., 2011; Tal et al., 2009). CI enzyme activity was analyzed with amicroplate
assay (Abcam, ab109721) using mitochondria isolated from tissue (Abcam,
ab110168) or cells (Abcam, ab110170).
Bone Analyses
Micro-CT was performed using a Scanco mCT-35 instrument (SCANCO Med-
ical) as described (Wei et al., 2010). Histomorphometry were performed as
described (Wan et al., 2007a; Wei et al., 2011). Serum CTX-1 and P1NP
were measured with RatLaps enzyme immunoassay (EIA) kit and Rat/Mouse
PINP EIA kit (Immunodiagnostic Systems). For LPS-induced bone loss, PBS
or LPS (5 mg/kg) was injected intraperitoneally into the 6- to 8-week-old
mice at day 0 and day 4, and the mice were killed on day 7.
Ex Vivo Macrophage and Osteoclast Differentiation
Macrophage and osteoclasts were differentiated from bone marrow cells as
described (Wan et al., 2007a). For macrophages, the cells were differentiated
with 20 ng/ml of mouse GM-CSF (R&DSystems) inminimumessential medium
alpha (a-MEM) containing 10% FBS for 6 days. For FA/LAC stimulation,
cells were treated with 400 mM PA or LA (Sigma; Wen et al., 2011) or 15 mM
L-(+)-lactic acid (Sigma; Samuvel et al., 2009) for 15 hr on day 6 unless indi-
cated otherwise. To inhibit mitochondrial ROS, macrophages were treated
with 50 mM 2R,4R-APDC, or Mito-TEMPO (Sigma) 24 hr before the addition
of fatty acids. For osteoclasts, the cells were differentiated with 40 ng/ml of
mouse M-CSF in a-MEM containing 10% FBS for 3 days (day 1–3), then
with 40 ng/ml of mouseMCSF and 100 ng/ml of mouse RANKL (R&D Systems)
for 3–9 days (day 4–12), with or without rosiglitazone (1 mM). Mature osteo-
clasts were identified as multinucleated (>3 nuclei) TRAP+ cells on day 12.
Osteoclast differentiation was quantified by the RNA expression of osteoclast
markers on day 6 using RT-quantitative PCR analysis. Osteoclast precursor
proliferation was quantified by bromodeoxyuridine incorporation (GE Health-
care). Osteoclast apoptosis was quantified with FACS analysis of AnnexinV+7-
AAD cells (BD Biosciences). To quantify osteoclast function, osteoclast
differentiation was conducted on OsteoAssay bone plates (Lonza), and oste-Figure 7. Fatty Acids and Lactate Exacerbate Osteoclastogenic Defec
(A–C) Bone marrow osteoclast differentiation cultures from WT or Ndufs4/ m
differentiation markers (n = 3). + compares with WT cells treated with vehicle (Veh
(D and E) Percentage of FMS+RANK+ osteoclast precursors in the bonemarrow (D
or without PA, LA (400 mM), or lactate (15 mM; E; n = 6).
(F–H) TLR2/4 deletion partially restored the osteoclastogenic defect inNdufs4/m
in osteoclast differentiation cultures treated with PA, LA (400 mM), or lactate (15
(I) A simplified model for how Ndufs4 and mitochondrial CI shift macrophage-oste
fatty acid oxidation; Inflam, inflammation; Diff, differentiation; Mito Bio, mitochon
496 Cell Metabolism 20, 483–498, September 2, 2014 ª2014 Elsevieoclast activity was measured as calcium release using CalciFluo ELISA assay
(Lonza).
Statistical Analyses
All statistical analyses were performed with Student’s t-test and represented
as mean ± SD unless noted otherwise. The p values were designated as
*p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001; and n.s., nonsignificant
(p > 0.05).
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